



Final Appraisal Recommendation
Advice No: 0918 – May 2018

**Selexipag (Uptravi®) 200 microgram, 400 microgram,
600 microgram, 800 microgram, 1,000 microgram,
1,200 microgram, 1,400 microgram,
1,600 microgram film-coated tablets**

Submission by Actelion Pharmaceuticals UK Ltd

Recommendation of AWMSG

Selexipag (Uptravi®) is recommended as an option for restricted use within NHS Wales.

Selexipag (Uptravi®) is licensed for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Selexipag (Uptravi®) is recommended as an option for restricted use within NHS Wales as a triple combination therapy for the treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) III who are insufficiently controlled on dual therapy with an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor.

Selexipag (Uptravi®) is not recommended for use within NHS Wales outside of this sub-population.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered selexipag (Uptravi®) satisfied the AWMSG criteria for a medicine developed specifically for rare diseases as an ultra-orphan equivalent medicine.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 700), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary

Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Date of first issue	May 2018
Last reviewed	December 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0918:
Selexipag (Upravi®) 200 microgram, 400 microgram, 600 microgram, 800 microgram,
1,000 microgram, 1,200 microgram, 1,400 microgram, 1,600 microgram. May 2018